Cambridge Consultants develops new wireless power transfer system

20 November 2017 (Last Updated November 20th, 2017 10:17)

Product design and development firm Cambridge Consultants has developed the new MagLense system to enable wireless power transfer to medical devices inside the body.

Cambridge Consultants develops new wireless power transfer system
MagLense provides flexible wireless power transfer to devices inside the body. Credit: Cambridge Consultants Ltd and Cambridge Consultants Inc.

Product design and development firm Cambridge Consultants has developed the new MagLense system to enable wireless power transfer to medical devices inside the body.

The flexible, efficient and safe procedure does not require precise alignment with the implant and can be used for patients of any shape and size without losing power.

MagLense is claimed to be self-calibrating to provide the optimum power for various locations, orientations, sizes and shapes of the implants.

The system is said to use several flexible coils to shape the applied magnetic field and specifically targets the desired implant, avoiding heat damage to other implants or surrounding tissue.

Cambridge Consultants implanted connectivity head Dr Arun Venkatasubramanian said: “This is a real breakthrough, addressing one of the core weaknesses in today’s implant design and solving many of the current clinical and patient challenges.

“This is a real breakthrough, addressing one of the core weaknesses in today’s implant design and solving many of the current clinical and patient challenges.”

“By using a power source completely separate from the body, and only when needed, a patient’s day-to-day routine will be transformed and their quality of life drastically improved.”

The configuration and control architecture of the system is intended to facilitate the transfer of efficient and higher rates of power to the implants.

MagLense is expected to enable new charging approaches such as on-demand wireless powering for various implants and aid in the treatment for patients with chronic and episodic disorders, including epilepsy, diabetes, obesity and depression.

The system is also expected to allow implantation in parts of the body that are not currently feasible and facilitate wide usage of micro-implants for targeted nerve stimulation.